Every material Form 8-K Silo Pharma, Inc. has filed with the SEC since August 19, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Silo Pharma, Inc. entered into securities purchase agreements on November 5, 2026, and closed a private placement with accredited investors on November 6, 2026. The company expects net proceeds of approximately $815,000 for working capital and general corporate purposes, and it agreed to register the resale of the shares and warrant shares with the SEC, which adds potential future share supply for existing shareholders.
Sold 136,005 shares of common stock at $1.50 per share
Issued pre-funded warrants for up to 430,661 shares of common stock at $1.4999 per warrant
Expected net proceeds of approximately $815,000 after placement agent fees and offering expenses
Must file a resale registration statement within 30 days of the November 5, 2026 registration rights agreement, with effectiveness targeted within 60 days (90 days if the SEC conducts a full review)
Silo Pharma signed an asset purchase agreement on October 13, 2026, to acquire certain software and related intellectual property from Larry King. The company paid by issuing 150,000 shares of common stock, which are locked up for up to 12 months. The filing does not state the value of the assets or the share price, so the deal's size relative to Silo's business cannot be assessed from this filing.
Agreement dated October 13, 2026, with Larry King as seller
Consideration: 150,000 shares of common stock, par value $0.0001 per share
Shares locked up until the earliest of 12 months, a Change in Control, or company consent
Seller indemnifies the company for misrepresentation, third-party infringement and gross negligence, fraud or intentional misconduct
Silo Pharma agreed on October 1, 2026 to buy software, technology and related intellectual property from Norsight Consulting Inc. In payment, it issued Norsight a warrant to buy up to 300,000 shares of common stock at $1.51 per share, a sale made without registration. The filing describes no cash consideration, so the deal adds potential dilution for shareholders while expanding the company's asset base.
Asset purchase agreement dated October 1, 2026 with Norsight Consulting Inc., an Arkansas corporation
Warrant covers up to 300,000 shares at an exercise price of $1.51 per share, exercisable from April 1, 2027 and expiring September 30, 2031
Seller may not hold more than 4.99% of outstanding common stock after exercise, and may not exceed 9.99% without at least 61 days' notice
Shares received by the seller are locked up for up to 12 months, or until a change in control or the company's written consent
Silo Pharma entered into an asset purchase agreement on August 18, 2026, to acquire software, technology, domain names and related intellectual property from Parkview Consulting LLC, paying with 165,000 newly issued common shares. The seller's sole member, Corwin Yu, currently serves as lead strategic advisor on the company's Cryptocurrency Advisory Board, a relationship the filing discloses. The shares are locked up for up to 12 months, and the seller gives indemnification protections.
Consideration: 165,000 shares of common stock, par value $0.0001 per share, issued to Parkview Consulting LLC
Lock-up runs until the earliest of 12 months, a Change in Control, or company written consent
Seller is owned by Corwin Yu, who is lead strategic advisor on the Cryptocurrency Advisory Board
Shares issued under Section 4(a)(2) of the Securities Act of 1933; agreement filed as Exhibit 10.1 with schedules omitted
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Silo Pharma, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →